Clarithromycin Versus Azithromycin in Treatment of Mild COVID-19 Infection

• Status: Completed
• Trial end date: 2020-07-30
• Target enrollment: 0
• Participant gender: All

Summary

The current study was conducted at Qena Governorate, Egypt, during the period from May 2020, to July 2020. The study included 305 COVID-19 cases diagnosed by PCR, patients were randomly assigned to one of three study limps, Azithromycin 500 mg/24 h for 7 days, Clarithromycin 500 /12 h for 7 days, or a control group with no antibiotics, All three groups received only symptomatic treatment for control of fever and cough

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: South Valley University
• Treatments: Azithromycin; Clarithromycin

Criteria

Inclusion Criteria:

• COVID-19 cases

• Oxygen saturation > 93%

• Age >18 years

Exclusion Criteria:

• Patients <18 years,

• patients with Oxygen saturation < 93%, patients with

• Diabetes mellitus or

• heart failure,

• patients on chemotherapy or immunosuppressive therapy